



CASE CT-2645A DIV1

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

James Epperson
Type or print name

James Epperson
Signature

April 21, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

YU ET AL.

APPLICATION NO: 10/643,411

FILED: AUGUST 19, 2003

FOR: HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE
ANTIVIRAL AGENTS

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
203-677-6974


James Epperson
Agent for Applicants
Reg. No. 52,867

Date: 4/21/2004

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
CT-2645A DIV1
APPLICATION NO.
10/643,411
APPLICANT
YU ET AL.
FILING DATE
AUGUST 19, 2003

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	TRADEMARK	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,066,656	11/19/91	Michael N. Greco, et al			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Dubovi, E. J. et al, "Inhibition of Respiratory Syncytial Virus by Bis(5-Amidino-2-Benzimidazolyl)Methane," VIROLOGY, 103(2), pp. 502-504, 1980
	AS	Pandey, V. K., "Search for New Antiviral Agents. Part V. Synthesis of Some 1,2 Disubstituted Benzimidazole Derivatives," J. INDIAN CHEM. SOC., 58(9), pp. 893-894, 1981 (CHEMICAL ABSTRACTS, Vol. 95 No. 28, Abstract No. 187156G, p. 645, 1981)
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

CERTIFICATE OF MAILING

USPTO
JAN 12 2004
PATENT & TRADEMARK OFFICE

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

James Epperson
Type or print name

James Epperson
Signature

January 8, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

YU ET AL.

APPLICATION NO: 10/643,411

FILED: AUGUST 19, 2003

FOR: HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE
ANTIVIRAL AGENTS

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/994,012 filed November 16, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
203-677-6974


James Epperson
Agent for Applicants
Reg. No. 52,867

Date: 1/8/2003

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT-2645A DIV1
APPLICATION NO.
10/643,411
APPLICANT
YU ET AL.
FILING DATE
August 19, 2003

Group --

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
BML	AA	4,324,794	4/13/82	R. R. Tidwell, et al			
	AB	5,256,668	10/26/93	K.-H. L. Hsu, et al			
BML	AC	3,394,141	7/23/68	F. Sparatore			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BML	AJ	EP 058146A1	8/18/82	US Patent 4,525,358 English Equivalent			<input type="checkbox"/>	<input type="checkbox"/>
	AK	AU-A-14,704	12/22/98	US Patent 5,852,015 English Equivalent			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 01/36395	5/25/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 00/38508	7/6/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01/00611	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 01/00612	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 01/00615	1/4/01	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
BML	AQ	WO 00/04900	2/3/00	PCT Patent Application			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BML	AR	E. J. Dubovi, et al, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 19(4), pp. 649-656, 1981
	AS	P. R. Wyde, et al, ANTIVIRAL RESEARCH, 38, pp. 31-42, 1998
BML	AT	F. Pagani, et al, BOLL. CHIM. FARM., 104, pp. 427-431, 1965

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT-2645A DIV1
APPLICATION NO.
10/643,411
APPLICANT
YU ET AL.
FILING DATE
August 19, 2003

Group --



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

Cite	AU	G. Paglietti, et al, IL. FARMACO-ED. SC., 30, pp. 505-511, 1975
	AV	S. Shigeta, et al, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 3(3), pp. 171-177, 1992
	AW	W. R. Roderick, et al, J. MED. CHEM., 15(6), pp. 655-658, 1972
	AX	B. Cakir, et al, GAZI ECZACILIK FAK. DER., 5(1), pp. 71-77, 1988
	AY	H. R. Howard, et al, EUR. J. MED. CHEM., 27, pp. 779-789, 1992
	AZ	F. Sparatore, et al, IL FARMACO ED. SCI., 33, pp. 901-923, 1978
	BA	JAMA, 277(1), pp. 12-13, 1997
	BB	E. De Clercq, INT. J. ANTIMICROBIAL AGENTS, 7, pp. 193-202, 1996
Bup	BC	R. R. Tidwell, et al, J. MED. CHEM., 26, pp. 294-298, 1983
	BD	
	BE	
	BF	
	BG	
	BH	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.